
|Articles|May 12, 2015
- NSCLC (Issue 7)
- Volume 7
- Issue 2
Characteristics of Additional KRAS Subsets in Lung Cancer
Author(s)John Heymach, MD, PhD
John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses the characteristics of three more KRAS subsets in lung cancer, which researchers discovered in a recent study.
Advertisement
John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses the characteristics of three more KRAS subsets in lung cancer, which researchers discovered in a recent study.
<<<
Articles in this issue
about 11 years ago
MET as a Secondary Driver in Lung Cancerabout 11 years ago
MiR-34a Link to PD-L1 May Mean New Immunotherapy in NSCLCabout 11 years ago
Treating EGFR Exon 19 Deletions in NSCLC: Q&A With Benjamin P. Levy, MDabout 11 years ago
More Endpoints Not Necessarily Merrier in NSCLC Drug Trialsabout 11 years ago
Combining Bevacizumab With EGFR TKIs in Lung Cancerabout 11 years ago
US-Cuban Partnership Developing Anticancer Vaccine for NSCLCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
2
Dostarlimab Demonstrates Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
3
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
4
B7-H3–Targeted ADC Risvutatug Rezetecan Extends Survival in Small Cell Lung Cancer
5






























